Hoba Therapeutic is an early-stage biotech based in Denmark developing innovative treatments for chronic pain disorders and sensorineural hearing loss - indications with a high unmet medical need for safe and efficacious treatments for millions of patients worldwide.
Our science is based on the discovery of a novel family of endogenous human proteins: meteorin and cometin. These neurotrophic factors are involved in the development, growth, survival, and maintenance of nerve cells, supporting glial cells and sensory pathways.
Hoba Therapeutics holds the right to two novel biopharmaceutical drugs
Latest News
1 March 2024
Hoba Therapeutics announces the appointment of Jean Combalbert as Chair of the Board of Directors.
11 December 2023
Hoba Therapeutics raises EUR 23 million in a Series A to advance new drug candidate against chronic neuropathic pain. The financing was co-led by Indaco Venture Partners and Medical Incubator Japan, and included investments from Novo Holdings, Eir Ventures, the Export and Investment Fund of Denmark (EIFO) and The European Innovation Council Fund.
6 July 2022
Eir Ventures, in partnership with the Danish Growth Fund, has completed an internal purchase of shares from Borean Innovation and is now an investor in Hoba Therapeutics.